The closing price of PTC Therapeutics Inc (NASDAQ: PTCT) was $44.34 for the day, down -0.89% from the previous closing price of $44.74. In other words, the price has decreased by -$0.89 from its previous closing price. On the day, 0.97 million shares were traded. PTCT stock price reached its highest trading level at $45.36 during the session, while it also had its lowest trading level at $44.17.
Ratios:
Our analysis of PTCT’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.73 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.07. For the most recent quarter (mrq), Quick Ratio is recorded 3.85 and its Current Ratio is at 3.89.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $80.
On May 09, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $68.
Citigroup Upgraded its Sell to Neutral on May 07, 2025, while the target price for the stock was maintained at $40.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 15 ’25 when Gravier Pierre sold 2,516 shares for $49.46 per share. The transaction valued at 124,441 led to the insider holds 71,920 shares of the business.
Gravier Pierre bought 2,516 shares of PTCT for $124,435 on Jul 15 ’25. On May 15 ’25, another insider, Boulding Mark Elliott, who serves as the EXEC. VP AND CLO of the company, sold 1,929 shares for $46.18 each. As a result, the insider received 89,081 and left with 103,901 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 3514255360 and an Enterprise Value of 3996219136. As of this moment, PTC’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.98. Its current Enterprise Value per Revenue stands at 2.254 whereas that against EBITDA is 4.461.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.52, which has changed by 0.34241593 over the last 52 weeks, in comparison to a change of 0.17535925 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $58.38, while it has fallen to a 52-week low of $29.01. The 50-Day Moving Average of the stock is -8.91%, while the 200-Day Moving Average is calculated to be -5.72%.
Shares Statistics:
PTCT traded an average of 1.21M shares per day over the past three months and 836560 shares per day over the past ten days. A total of 79.23M shares are outstanding, with a floating share count of 75.73M. Insiders hold about 4.45% of the company’s shares, while institutions hold 98.90% stake in the company. Shares short for PTCT as of 1752537600 were 5772442 with a Short Ratio of 4.77, compared to 1749772800 on 5072028. Therefore, it implies a Short% of Shares Outstanding of 5772442 and a Short% of Float of 8.37.
Earnings Estimates
Investors are keenly observing as 5.0 analysts analyze and rate the current performance of PTC Therapeutics Inc (PTCT) in the stock market.The consensus estimate for the next quarter is -$0.75, with high estimates of $0.19 and low estimates of -$1.14.
Analysts are recommending an EPS of between $8.61 and $6.97 for the fiscal current year, implying an average EPS of $7.57. EPS for the following year is -$1.87, with 5.0 analysts recommending between $1.67 and -$3.12.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 13 analysts. It ranges from a high estimate of $198.5M to a low estimate of $146.7M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $186.7MFor the next quarter, 13 analysts are estimating revenue of $194.76M. There is a high estimate of $313.77M for the next quarter, whereas the lowest estimate is $152.9M.
A total of 16 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.85B, while the lowest revenue estimate was $707M, resulting in an average revenue estimate of $1.62B. In the same quarter a year ago, actual revenue was $806.78MBased on 16 analysts’ estimates, the company’s revenue will be $863.26M in the next fiscal year. The high estimate is $1.24B and the low estimate is $691.8M.
